Abstract:The heavy glycosylation on HIV-1 envelope protein (Env) plays an important role in viral evasion and is critical for the viral plasticity and diversity in the circulating strains. The discovery of a new class of broadly neutralizing antibodies (bnAbs), including PG9, PGT128, PGT121, and 10-1074, that recognize conserved glycopeptide epitopes from the V1V2 and V3 domains provide a valuable template for vaccine design. Structural and mutational studies have provided basic information on the nature and structure of the glycopeptide epitopes of these antibodies. Nevertheless, due to the tremendous heterogeneity of envelope glycosylation, the fine glycan specificity of these antibodies remains to be fully characterized. Moreover, it remains a challenging task to reconstruct glycosylation-well defined antigenic structures even when the glycan specificity is defined. To address these problems, we have launched a chemical biology program aiming to reconstitute a library of structurally well-defined glycopeptides and glycoproteins to probe the glycan specificity of these glycan-reactive broadly neutralizing antibodies. Through the chemoenzymatic synthesis and antibody-binding studies of a library of V3 glycopeptides, we found that the PGT128 requires a high-mannose N-glycan on V3 domain with promiscuous site of glycosylation at either N332, N301, orN295); the PGT121 shows binding specificity towards a sialylated N-glycan at N301 site; and the 10-1074 prefers a high-mannose type glycan at N332 site. From the mapping of the epitopes, we designed glycopeptide-based immunogens derived from the V3 domain through chemical and biological approaches. The synthetic glycopeptide immunogens obtained by chemoenzymatic synthesis and the glycosylation-defined V3 glycopeptide-Fc fusion proteins obtained through mammalian cell expression both showed potent binding towards multiple V3-targeting bnAbs. Rabbit immunization experiments revealed that the synthetic V3 glycopeptide could elicit glycan-dependent antibody responses. These results together suggested that our glycosylation-defined V3 glycopeptide immunogens could serve as a valuable vaccine component in the combination with other vaccine candidates for further immunization studies.

Chemical Synthesis of Highly Congested Gp120 V1V2 N-Glycopeptide Antigens for Potential HIV-1-Directed Vaccines

Recognition Of Synthetic Glycopeptides By Hiv-1 Broadly Neutralizing Antibodies And Their Unmutated Ancestors

PI-6 Construction and Analysis of V3 Glycopeptide Antigens for HIV-1 Vaccine Design

Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide

Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates

Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine

Systematic Synthesis and Binding Study of HIV V3 Glycopeptides Reveal the Fine Epitopes of Several Broadly Neutralizing Antibodies

Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection

Altering the Specificity of the Antibody Response to HIV Gp120 with a Glycoconjugate Antigen.

Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates

Multiple antigen peptide mimetics containing gp41 membrane-proximal external region elicit broad neutralizing antibodies against human immunodeficiency virus type 1 in guinea pigs.

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

Generation and Characterization of a Bivalent HIV-1 Subtype C Gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N-Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition.

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein

Enhancement of Human Immunodeficiency Virus Type 1 Infection by Antisera to Peptides from the Envelope Glycoproteins Gp120/gp41.

Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine.